Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPHT message board posts where the ticker symbol OPHT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPHT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001193125-18-189510 (34 Act)  Size: 38 KB
2018-06-11 005-87636
18892505
8-K  Documents Current report, item 1.01
Acc-no: 0001410939-18-000039 (34 Act)  Size: 40 KB
2018-06-07 001-36080
18885190
8-K  Documents Current report, items 5.02 and 5.07
Acc-no: 0001410939-18-000035 (34 Act)  Size: 42 KB
2018-05-29 001-36080
18862955
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001410939-18-000033 (34 Act)  Size: 35 KB
2018-05-15 001-36080
18836307
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001410939-18-000031 (34 Act)  Size: 37 KB
2018-05-14 001-36080
18828661
8-K  Documents Current report, item 5.02
Acc-no: 0001410939-18-000030 (34 Act)  Size: 22 KB
2018-05-14 001-36080
18828658
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001410939-18-000025 (34 Act)  Size: 4 MB
2018-05-09 001-36080
18818387
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001410939-18-000023 (34 Act)  Size: 121 KB
2018-05-09 001-36080
18816655
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001410939-18-000020 (34 Act)  Size: 3 MB
2018-04-17 001-36080
18757907
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-022242 Size: 9 KB
2018-04-03
More OPHT SEC Filings


Related news from
Fri, 08 Jun 2018
12:41:12 +0000
Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session
Ophthotech (OPHT) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Fri, 08 Jun 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation
NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.
Thu, 07 Jun 2018
11:00:00 +0000
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.
Wed, 16 May 2018
03:52:15 +0000
Edited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Ophthotech Corp Earnings Call
Mon, 14 May 2018
11:30:00 +0000
Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PHH ...
Thu, 10 May 2018
14:41:02 +0000
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.
Wed, 09 May 2018
11:39:25 +0000
Ophthotech: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 36 cents. The company's shares closed at $2.62. A year ago, they were trading at $2.62. _____ This story was generated by Automated ...
Wed, 09 May 2018
11:00:00 +0000
Ophthotech Reports First Quarter 2018 Financial and Operating Results
Ophthotech Corporation today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.
Thu, 03 May 2018
11:10:00 +0000
Wired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPHT as the Company's latest news hit the wire. On May 01, 2018, the New York-based biopharmaceutical Company announced that it has completed patient enrollment in its Phase-2a clinical trial of Zimura® (avacincaptad pegol) in patients with wet age-related macular degeneration (AMD).
Tue, 01 May 2018
11:35:00 +0000
Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura® in Combination with Anti-VEGF Therapy in Wet Age-Related Macular Degeneration
Ophthotech Corporation (OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. “We are pleased with the enthusiasm shown by the principal investigators in the recruitment for this clinical trial leading to on time enrollment of patients,” stated Kourous Rezaei, M.D., Chief Medical Officer of Ophthotech.
Tue, 01 May 2018
11:30:00 +0000
Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Ophthotech Corporation (OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.
Tue, 20 Mar 2018
21:48:09 +0000
Regeneron Eylea Hits 24-Week Primary Endpoint in Study
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.
Mon, 19 Mar 2018
16:45:10 +0000
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
Tue, 06 Mar 2018
12:30:00 +0000
Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference
Ophthotech Corporation announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m.
Thu, 01 Mar 2018
12:20:00 +0000
Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases
Stock Monitor: Spark Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 01, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT ). If ...
Wed, 28 Feb 2018
14:04:02 +0000
Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
Wed, 28 Feb 2018
01:01:12 +0000
Edited Transcript of OPHT earnings conference call or presentation 27-Feb-18 1:00pm GMT
Q4 2017 Ophthotech Corp Earnings Call
Tue, 27 Feb 2018
11:59:07 +0000
Ophthotech reports 4Q loss
On a per-share basis, the New York-based company said it had a loss of 26 cents. For the year, the company reported net income of $114.2 million, or $3.17 per share, swinging to a profit in the period. ...
Tue, 27 Feb 2018
11:33:00 +0000
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Ophthotech Corporation today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.
Tue, 27 Feb 2018
11:30:00 +0000
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy
Ophthotech Corporation announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation therapies for the treatment of ocular diseases.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "It [ValueForum] has provided me with eye opening information on a wide scale. The collective wisdom of the membership is astounding and somewhat intimidating; but useful input is appreciated pretty universally." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards